Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dynavox Group AB (publ) (DYVOX.ST)
Stockholm, SE
Headquartered in Stockholm, Sweden, Dynavox Group AB (publ), founded in 2012, specializes in crafting and distributing assistive technology. The company primarily assists individuals with significant communication challenges by providing bespoke augmentative and alternative communication (AAC) solutions. These innovative systems empower people living with conditions like cerebral palsy, ALS, autism spectrum disorder, and spinal cord injury to express themselves effectively and autonomously. Their holistic communication package encompasses specialized language frameworks, dedicated software, hardware devices, financial support guidance, comprehensive user assistance, and training initiatives. Dynavox Group maintains a global presence, conducting operations across Sweden, Norway, Denmark, Belgium, the United States, Germany, France, China, the United Kingdom, Ireland, Australia, and New Zealand. The company underwent a name change in July 2024, transitioning from its former identity as Tobii Dynavox AB (publ).
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.36% | -3.97% | -15.08% | -18.49% | -25.50% | -28.87% | -35.39% | +177.62% | +133.67% | +133.67% | +133.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+25.1% ★ Q1'26: +1.2% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+13.9% Q1'26: +63.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-1.2% Q1'26: +9.4% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+10.1% Q1'26: +8.7% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+13.2% ★ Q1'26: +10.5% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.3% Q1'26: +0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×2.32× Q1'26: 3.55× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 4 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
1.97B
est: 1.94B (+1.5%)
|
2.47B
est: 2.48B (-0.5%)
|
2.82B
2.69B – 2.94B
+13.8% YoY
|
3.34B
3.11B – 3.54B
+18.2% YoY
|
3.88B
3.87B – 3.90B
+16.4% YoY
|
4.50B
4.24B – 4.74B
+16.0% YoY
|
| EBITDA |
425.10M
est: 638.35M (-33.4%)
|
476.50M
est: 814.58M (-41.5%)
|
927.05M
883.87M – 966.22M
+13.8% YoY
|
1.10B
1.02B – 1.16B
+18.2% YoY
|
1.28B
1.27B – 1.28B
+16.4% YoY
|
1.48B
1.39B – 1.56B
+16.0% YoY
|
| EBIT |
225.10M
est: 308.86M (-27.1%)
|
248.80M
est: 394.13M (-36.9%)
|
448.55M
427.66M – 467.50M
+13.8% YoY
|
530.34M
494.35M – 562.32M
+18.2% YoY
|
617.16M
614.58M – 619.74M
+16.4% YoY
|
716.12M
674.51M – 753.37M
+16.0% YoY
|
| Net Income |
145.80M
est: 160.81M (-9.3%)
|
165.70M
est: 222.98M (-25.7%)
|
306.19M
293.00M – 363.77M
+37.3% YoY
|
430.24M
394.91M – 506.80M
+40.5% YoY
|
557.08M
511.41M – 674.84M
+29.5% YoY
|
785.59M
726.26M – 838.71M
+41.0% YoY
|
| SGA |
951.70M
est: 930.69M (+2.3%)
|
1.18B
est: 1.19B (-0.6%)
|
1.35B
1.29B – 1.41B
+13.8% YoY
|
1.60B
1.49B – 1.69B
+18.2% YoY
|
1.86B
1.85B – 1.87B
+16.4% YoY
|
2.16B
2.03B – 2.27B
+16.0% YoY
|
| EPS |
1.39
est: 1.51 (-7.9%)
|
1.57
est: 2.10 (-25.3%)
|
3.08
2.75 – 3.42
+46.4% YoY
|
4.25
3.71 – 4.76
+38.1% YoY
|
5.48
4.80 – 6.34
+28.8% YoY
|
7.38
6.82 – 7.88
+34.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-11 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-10 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-09 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-08 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-05 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-04 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-03 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-02 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-01 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis International Small Cap Value ETF AVDV | 0.08% | 14.88M | 0.36% |
| 2 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.08% | 877.8K | 0.40% |
| 3 | iShares Ageing Population UCITS ETF AGED.L | 0.06% | 513.7K | 0.40% |
| 4 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.04% | 1.50M | 0.30% |
| 5 | iShares MSCI Europe Small-Cap ETF IEUS | 0.04% | 71.9K | 0.41% |
| 6 | Avantis International Small Cap Equity ETF AVDS | 0.04% | 117.2K | 0.30% |
| 7 | State Street SPDR S&P International Small Cap ETF GWX | 0.04% | 314.5K | 0.40% |
| 8 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.03% | 323.0K | 0.39% |
| 9 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.03% | 102.0K | 0.23% |
| 10 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.03% | 102.0K | 0.23% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fredrik Ruben | Chief Executive Officer | 6M | male |
| Elisabeth Manzi | Corporate Communications Director | — | female |
| Kristen Cook | Chief Marketing Officer | — | female |
| Linda Tybring | Chief Financial Officer | — | female |
| Luis Mustafa | Chief Operations Officer | — | male |
| Marie-Josée Leblond | Chief Digitalization & Information Officer | — | female |
| Markus Cederlund | Chief Product & Development Officer | — | male |
| Mikael Backstrom | Chief People & Sustainability Officer | — | male |
| Nils Normell | President of Europe & the rest of the world -EUROW | — | male |
| Anthony Pavlik | Chief Operations Officer | — | male |
| Tara Rudnicki | President of North America | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DYVOX.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
